Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells

28 Dec 2020

Abstract excerpt

Palbociclib, a selective CDK4/6 kinase inhibitor, is approved in combination with endocrine therapies for the treatment of advanced estrogen receptor positive (ER+) breast cancer. In pre-clinical cancer models, CDK4/6 inhibitors act primarily as cytostatic agents. In two commonly studied ER+ breast cancer cell lines (MCF7 and T47D), CDK4/6 inhibition drives G1-phase arrest and the acquisition of a senescent-like...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Metabolism, Diabetes, and Cancer
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33356791
DOI: 10.1080/15384101.2020.1859195

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cellsPMID 33356791Read ↗

Active growth signalling promotes cancer cell sensitivity to the CDK7 inhibitor ICEC0942Semantic proximity Read ↗

CDK4/6 inhibitor: from quiescence to senescenceSemantic proximity Read ↗

mTOR is a Major Determinant of ChemosensitivitySemantic proximity Read ↗

Non-Canonical Senescence Phenotype in Resistance to CDK4/6 Inhibitors in ER-Positive Breast CancerSemantic proximity Read ↗

Reversal of phenotypes of cellular senescence by pan-mTOR inhibition.Semantic proximity Read ↗

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast CancerSemantic proximity Read ↗

Oncogene-induced senescence and senescence-associated secretory phenotype (SASP) determine the efficacy of palbociclib in PIK3CA mutated colorectal cancerSemantic proximity Read ↗

GREB1 regulates proliferation of estrogen receptor positive breast cancer through modulation of PI3K/Akt/mTOR signalingSemantic proximity Read ↗

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models.Semantic proximity Read ↗

Cyclin D1 Activity Regulates Autophagy and Senescence in the Mammary EpitheliumSemantic proximity Read ↗

Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancerSemantic proximity Read ↗

Low expression of PCK2 in breast tumors contributes to better prognosis by inducing senescence of cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.